Navigation Links
Onyx Pharmaceuticals Reports Third Quarter 2011 Financial Results
Date:11/2/2011

to regorafenib, a late-stage oncology compound. 

On a GAAP basis, Onyx reported a net loss of $36.9 million, or $0.58 per diluted share, for the third quarter 2011 compared to a net income of $41.5 million, or $0.66 per diluted share, for the same period in 2010. A description of the non-GAAP calculations and reconciliation to comparable GAAP measures is provided in the accompanying table entitled "Reconciliation of GAAP to Non-GAAP Net Income (Loss)."

Revenue from Collaboration AgreementGlobal Nexavar net sales, which are recorded by Onyx's collaborator, Bayer, were $250.3 million for the third quarter 2011, an increase of $24.1 million, or 11%, compared to $226.2 million for the same period in 2010. Onyx and Bayer are marketing and developing Nexavar® (sorafenib) tablets, an anticancer therapy currently approved for the treatment of unresectable liver cancer and advanced kidney cancer in over 100 countries worldwide.

For the third quarter 2011, Onyx reported total revenue from collaboration agreement of $75.0 million compared to $63.7 million for the same period in 2010.

License RevenueIn the third quarter 2010, Onyx recorded license revenue of $59.2 million, reflecting a fee earned as a part of the consideration under the September 2010 exclusive license agreement with Ono Pharmaceutical Co., Ltd.

Operating ExpensesOnyx recorded research and development expenses of $58.5 million in the third quarter 2011 compared to $44.6 million for the same period in 2010. The increase in research and development expense was primarily due to investments in the development of carfilzomib, particularly the Phase 3 ASPIRE and FOCUS trials as well as increased investment in the manufacturing of carfilzomib.  

Selling, general and administrative expenses were $42.6 million in the third quarter 2011, compared to $25.9 million for the same period in 2010. Higher selling, general and administrative
'/>"/>

SOURCE Onyx Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)...  The board of directors of AbbVie Inc. (NYSE: ... of $0.42 per share.  The cash ... record at the close of business on Oct. 15, ... research-based biopharmaceutical company formed in 2013 following separation from ... dedicated people and unique approach to innovation to develop ...
(Date:9/19/2014)... WHITEHOUSE STATION, N.J. , Sept. 19, 2014 Merck ... the United States and Canada , ... on Desafiando La Diabetes: Logra Tus Metas , an educational ... of their blood sugar -- a key treatment goal to help ... the United States are at a higher risk for ...
(Date:9/19/2014)... 19, 2014 Larry J. Merlo , President ... will speak before the National Press Club in ... recent move to stop selling tobacco products and its leadership ... health. "Dramatic changes in our health care system ... government," Merlo has said. "CVS Health has a truly unique ...
Breaking Medicine Technology:Celebrity Chef Leticia Moreinos Schwartz Partners with Merck on Desafiando La Diabetes: Logra Tus Metas to Urge Hispanics With Type 2 Diabetes to Get to Their A1C Goal 2Celebrity Chef Leticia Moreinos Schwartz Partners with Merck on Desafiando La Diabetes: Logra Tus Metas to Urge Hispanics With Type 2 Diabetes to Get to Their A1C Goal 3Celebrity Chef Leticia Moreinos Schwartz Partners with Merck on Desafiando La Diabetes: Logra Tus Metas to Urge Hispanics With Type 2 Diabetes to Get to Their A1C Goal 4Celebrity Chef Leticia Moreinos Schwartz Partners with Merck on Desafiando La Diabetes: Logra Tus Metas to Urge Hispanics With Type 2 Diabetes to Get to Their A1C Goal 5CVS Health CEO to Address National Press Club on Landmark Decision to Quit Tobacco, Leadership in Health Care Innovation 2CVS Health CEO to Address National Press Club on Landmark Decision to Quit Tobacco, Leadership in Health Care Innovation 3
(Date:9/20/2014)... "As a nurse, patients always ask me how ... from Tamaqua, Pa. "The reason that they cannot tell is ... chairs. My invention enables them to check oxygen levels on ... make it easier to monitor the contents of an oxygen ... tank is low. It allows changeovers to be performed under ...
(Date:9/20/2014)... Los Angeles, CA (PRWEB) September 20, 2014 ... power score of 3.1 out of 5, indicating a ... research firm IBISWorld, this score reflects current and future ... negotiate from historically high prices. Other factors that negatively ... volatility in demand for construction and the moderate switching ...
(Date:9/20/2014)... Wisconsin (PRWEB) September 20, 2014 QueenBeeTickets.com ... the young star’s tour performances. She will visit many ... of February until the 16th of April. , ... Grande Honeymoon Tour tickets at QueenBeeTickets.com. , The star’s ... opportunity to see their favorite young singer in a ...
(Date:9/20/2014)... (PRWEB) September 20, 2014 Final Cut ... announced the release of the Information theme for FCPX filmmakers. ... use to describe the Information theme,” says Christina Austin, CEO ... to look so professional.” , Information features easy to use ... parameters of the environment. Change the background color, color of ...
(Date:9/20/2014)... 2014 The first federal bellwether trial ... its third week in the U.S. District Court, Northern ... documents indicate that the week opened in the ... a DePuy Orthopaedics vice president, who discussed the clinical ... Pinnacle hip replacement. According to Reuters, the executive stated ...
Breaking Medicine News(10 mins):Health News:Plumbing Construction Services Procurement Category Market Research Report from IBISWorld Has Been Updated 2Health News:Plumbing Construction Services Procurement Category Market Research Report from IBISWorld Has Been Updated 3Health News:Plumbing Construction Services Procurement Category Market Research Report from IBISWorld Has Been Updated 4Health News:Discount Ariana Grande Tickets: QueenBeeTickets.com Delights Fans with Discount Concert Tickets for Ariana Grande’s 2015 Honeymoon Tour 2Health News:Today Pixel Film Studios Announced the Release of the Information Theme for Final Cut Pro X 2Health News:Third Week of DePuy Pinnacle Hip Lawsuit Trial Focuses on Clinical Testing of Metal-on-Metal Hip Implant, Wright & Schulte LLC Reports 2Health News:Third Week of DePuy Pinnacle Hip Lawsuit Trial Focuses on Clinical Testing of Metal-on-Metal Hip Implant, Wright & Schulte LLC Reports 3Health News:Third Week of DePuy Pinnacle Hip Lawsuit Trial Focuses on Clinical Testing of Metal-on-Metal Hip Implant, Wright & Schulte LLC Reports 4
... Susan Desmond-Hellmann, MD, MPH, will be inducted today ... alongside some of the world,s other most distinguished ... a renowned oncologist and biotechnology leader who now ... was among five members of the 210 new ...
... technique appears to offer quick and effective relief for ... cancer, researchers reported at the 35th Congress of the ... Many patients with multiple myeloma, or those whose cancer ... fractures in their spine. This is partly because the ...
... Diseases, part of the National Institutes of Health, has ... Virginia Bioinformatics Institute (VBI) and collaborators to determine how ... of the gut. The funding will be used to ... to gut pathogens. "The Center for Modeling Immunity ...
... HealthDay Reporter , FRIDAY, Oct. 8 (HealthDay News) -- Researchers ... may double the odds that a child will develop a ... The study authors aren,t calling for an end to childhood ... such as pneumonia and broken bones. And the study doesn,t ...
... treatment has shown encouraging activity as a first-line therapy ... Congress of the European Society for Medical Oncology (ESMO) ... MD, Mayo Clinic in Florida, presented the results of ... a first-line treatment for metastatic breast cancer. ...
... the European Health Award 2010 handed to the Chronic Disease ... 6 9 October 2010. The ESC was instrumental ... health professionals. The stepping stone was a policy conference organised ... together 10 European health organisations. In just a year, the ...
Cached Medicine News:Health News:UCSF Chancellor inducted into Academy of Arts and Sciences 2Health News:UCSF Chancellor inducted into Academy of Arts and Sciences 3Health News:Surgical technique relieves painful spine fractures in patients with metastatic cancer 2Health News:Virginia Bioinformatics Institute to model immune responses to gut pathogens 2Health News:Virginia Bioinformatics Institute to model immune responses to gut pathogens 3Health News:3 or More X-Rays May Raise Leukemia Risk Among Kids: Study 2Health News:3 or More X-Rays May Raise Leukemia Risk Among Kids: Study 3Health News:Targeted therapy promising for HER2-positive metastatic breast cancer 2Health News:Chronic Disease Alliance receives European Health Award 2010 2Health News:Chronic Disease Alliance receives European Health Award 2010 3Health News:Chronic Disease Alliance receives European Health Award 2010 4
... Freedom® CMC ThumbFit™ reduces joint ... low-profile splint is remarkably comfortable and ... adjust.,Pamela Kirby, OTR/L, CHT and Robert ... the splint together in response to ...
... Blue Line ThumStay offers thumb and wrist ... soft, breathable foam. Lightweight stays provide firm ... can easily be contoured for proper positioning ... deQuervain's tenosynovitis, tendinitis, CMC joint arthritis, and ...
... Soft, foam-lined FoamWrap ThumWrap Splints offer support ... Ideal to relieve mild pain or strain ... activities. Choose either the rigid or the ... amount of support. Washable and breathable, the ...
... orthosis is designed to comfortably restrict motion ... the hand in a neutral position. It ... thermoplastic whose unique characteristics offer durable performance ... rigid cast-like immobilization of the wrist, hand, ...
Medicine Products: